This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -16.61% and 0.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.
Company News for Jul 8, 2021
by Zacks Equity Research
Companies in The News Are: BHVN, MSM, SGH, NKLA
New Strong Sell Stocks for June 14th
by Zacks Equity Research
CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 35.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention
by Zacks Equity Research
The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.
New Strong Sell Stocks for May 24th
by Zacks Equity Research
ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021
Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates (Revised)
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -44.178% and 0.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -1.71% and 0.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why
by Zacks Equity Research
Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Biohaven (BHVN) Might Surprise This Earnings Season
by Zacks Equity Research
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans
by Zacks Equity Research
Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.
Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data
by Zacks Equity Research
Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
by Zacks Equity Research
Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.